{"id":5137,"date":"2025-05-15T07:59:48","date_gmt":"2025-05-15T07:59:48","guid":{"rendered":"https:\/\/www.vampire-eu.com\/?page_id=5137"},"modified":"2026-01-20T15:52:48","modified_gmt":"2026-01-20T15:52:48","slug":"team","status":"publish","type":"page","link":"https:\/\/www.vampire-eu.com\/fr\/team\/","title":{"rendered":"Team"},"content":{"rendered":"
\n

Meet the Team<\/h1><\/div><\/div><\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\n

The Team<\/h2><\/div>\n<\/div>\n<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Linkcare Health Services SL<\/a><\/span>

Robert Jenkins<\/h3><\/div><\/div>

Dr. Robert Jenkins holds a PhD in Molecular Neuroscience from the University of Cambridge and an MBA from IESE Business School. He has a solid track record in leading multidisciplinary teams, driving scientific innovation, and managing high-impact international projects. He is the current CEO of Linkcare Health Services, where he contributes his expertise in product development, technology transfer, and regulatory approval. Dr. Jenkins holds key positions at Ferrer InCode and Werfen, leading market access strategies, international agreements, and M&A processes in the in vitro diagnostics field. He also has extensive experience in global consulting and manages collaborative R&D projects involving clinical validation and market deployment across Europe, the United States, Latin America, and Asia.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Casa di Cura IGEA<\/a><\/span>

Elda Judica<\/h3><\/div><\/div>

Elda Judica, MD, is Neurologist, Neurophysiologist and Senior Researcher at Casa di Cura Igea, Milan. She is also Director of Igea Biobank, responsible of the Centers for Cognitive Disorders and Dementia and for the Rare Diseases. From 2018 she has been responsible for the clinical coordination of national and international European-funded projects such as Virtual Coaching activities for rehabilitation in elderly (vCare), pain in stroke (PainRelife), integrated care in Parkinson’s Disease (ProCare4Life), and more recently for the Horizon Europe project VaMPiRE on validation of biological biomarkers in Parkinson’s Disease. She is also actively involved in several clinical pharmacological trials as Sub investigator on Alzheimer\u2019s Disease and Principal Investigator on CIDP.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Asociaci\u00f3n Parkinson Madrid<\/a><\/span>

Mayca Mar\u00edn<\/h3><\/div><\/div>

Mayca Mar\u00edn is General Health Psychologist and Social Worker specialized in gerontology and innovation. She is the European and National Project Coordinator at APM, leading initiatives to improve life quality for people with Parkinson\u2019s disease. These include projects on health and social care, therapeutic support, volunteering, leisure, community engagement, and tech integration. She plays a key role in coordinating European projects promoting personalized, integrated care for older adults. Her expertise includes project management, cross-sector collaboration, and implementing innovative strategies. This is possible thanks to the work of APM\u2019s team of 60+ professionals and 100+ volunteers supporting over 1,800 people and families in Madrid.)<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Universitaetsmedizin Goettingen<\/a><\/span>

Tiago Outeiro<\/h3><\/div><\/div>

Tiago Outeiro graduated in Biochemistry at the University of Porto and did his PhD thesis at the Whitehead Institute for Biomedical research \u2013 MIT. Tiago was a Postdoctoral Research Fellow in the Department of Neurology of the Massachusetts General Hospital, Harvard Medical School, and is currently Full Professor and the Director of the Department of Experimental Neurodegeneration at the University Medical Center Goettingen, in Germany.
Tiago holds a joint Professor position at Newcastle University in the UK. Tiago has authored >360 research articles and participates in various international boards and in collaborative projects with the aim of identifying the molecular basis of neurodegenerative disorders such as Alzheimer\u2019s and Parkinson\u2019s disease.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Fondazione European Brain Research Institute Rita Levi<\/a><\/span>

Marco Feligioni<\/h3><\/div><\/div>

Marco Feligioni, titulaire d'un doctorat, est pharmacologue et dirige le laboratoire Modifications post-traductionnelles des prot\u00e9ines et m\u00e9canismes de lib\u00e9ration des neurotransmetteurs \u00e0 l'Institut europ\u00e9en de recherche sur le cerveau (EBRI) \u00e0 Rome. Ses recherches portent sur les m\u00e9canismes mol\u00e9culaires sous-jacents aux maladies neurod\u00e9g\u00e9n\u00e9ratives telles que la maladie d'Alzheimer, la maladie de Parkinson et la SLA. Il \u00e9tudie l'impact des modifications post-traductionnelles, notamment la SUMOylation, sur les prot\u00e9ines li\u00e9es \u00e0 la neurod\u00e9g\u00e9n\u00e9rescence afin de d\u00e9terminer leurs r\u00f4les protecteurs ou nocifs. Il explore \u00e9galement la SUMOylation comme biomarqueur p\u00e9riph\u00e9rique. Auteur de nombreuses publications, le Dr Feligioni est l'initiateur et le coordinateur scientifique du projet VaMPiRE et du r\u00f4le de l'EBRI au sein du consortium.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Almawave SPA<\/a><\/span>

Raniero Romagnoli<\/h3><\/div><\/div>

Raniero Romagnoli is the CTO at Almawave. Within Almawave Group he is also CEO at OBDA Systems. He is an expert in AI and NLP and he drives the company technology strategy while managing technical teams of R&D and Innovation and the product group. Raniero actively participates in various national and international initiatives in the field of AI, also in collaboration with market associations, research centers and academies, and is member of the quality assurance committee of different universities and member of a European language technology industry association. He is currently a contract professor at two universities and a business school, teaching AI and ML both to Executive and MBA students and to university students.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
SYNLAB Italia S.R.L.<\/a><\/span>

Mariarosaria Incoronato<\/h3><\/div><\/div>

Mariarosaria Incoronato, Ph.D., is a molecular biologist with over 20 years of experience in clinical research. She earned her Ph.D. in Genetics of Microorganisms from the University of Naples \u201cFederico II\u201d in 2004. From 2005 to 2022, she worked as a biologist and researcher at SDN\/IRCCS-SDN S.p.A., and also held teaching roles at the University of Naples \u201cFederico II\u201d. She has coordinated several research projects funded by the Italian Ministry of Health, focusing on biomarkers in oncology, fatty liver, and heart failure. She is the author of 46 international publications (h-index: 24). Since 2022, she has been Scientific Assistant at Synlab Italia, supporting scientific research and health innovation.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Universitat Aut\u00f2noma de Barcelona<\/a><\/span>

Salvador Ventura<\/h3><\/div><\/div>

Salvador Ventura is Professor of Biochemistry and Molecular Biology at UAB, ICREA Acad\u00e8mia researcher, and since 2024, Scientific Director of I3PT-CERCA. He earned his PhD in Biological Sciences in 1998 and trained at EMBL-Heidelberg, Harvard Medical School, and Karolinska Institutet. He leads the \u201cProtein Folding and Conformational Disorders\u201d group at IBB-UAB, which he directed from 2017 to 2020. His lab integrates computational and experimental approaches to develop therapies targeting protein aggregation. He has led 47 competitive projects, 11 industry collaborations, authored over 310 papers, supervised 20 PhD theses, co-invented 19 patent families, and co-founded Eureka NanoBioEngineering. He ranks among the top 2% most influential scientists globally and has received major national awards for his research excellence.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Aristotelio Panepistimio Thessalonikis<\/a><\/span>

Dimitrios Kazis<\/h3><\/div><\/div>

Dr. Dimitrios Kazis is an Associate Professor of Neurology at the School of Medicine, Aristotle University of Thessaloniki, and Head of the 3rd Department of Neurology at \u201cG. Papanikolaou\u201d Hospital. He earned his MD and PhD from Aristotle University and completed advanced training in Neurology, Psychiatry, and Clinical Neurophysiology in the UK, and the USA. His clinical and research focus includes Parkinson\u2019s disease, MS, and Alzheimer\u2019s disease. He has participated in numerous national and international studies and published 76 research articles indexed in PubMed. He is actively involved in several international boards and collaborative projects for Alzheimer\u2019s and Parkinson\u2019s disease.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Institut National De La Sant\u00e9 Et De La Recherche Medicale<\/a><\/span>

Chiara Guerrera<\/h3><\/div><\/div>

Chiara Guerrera, PhD, HDR<\/strong>
Director, Translational Proteomics Lab, INSERM, Paris. Expert in mass spectrometry-based proteomics for precision medicine. Leads platform development at Necker Hospital with over 100 collaborations. PhD (UCL), postdoc at WIBR. Technologies: DIA-MS, ion mobility, SILAC, ITRAQ. Co-organizer of national proteomics schools\/events, jury member for HCERES, PhD & HDR. 103 publications (H-index 26). Grants: Horizon EU, RHU, ANR, etc. Multilingual: IT, EN, FR, ES.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Instytut Psychiatrii I Neurologii<\/a><\/span>

Tomasz St\u0119pie\u0144<\/h3><\/div><\/div>

Tomasz St\u0119pie\u0144 is an Associate Professor of Medical Sciences at the Department of Neuropathology, Institute of Psychiatry and Neurology in Warsaw. He heads the Polish Brain Bank, one of the largest worldwide, and serves as Secretary of the Polish Association of Neuropathologists. He initiated the \u201cDigital Brain\u201d project and develops digital tools for neuropathology. He is the author and co-author of numerous publications in neuropathology, psychiatry, and neurology. His research focuses on neurodegenerative diseases and the interface between psychiatry and neurology. He holds a patent, teaches, promotes science, and coordinates the Polish part of the Horizon Europe project VaMPiRE.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
LEITAT<\/a><\/span>

Joan Marc Cabot<\/h3><\/div><\/div>

Joan Marc Cabot, docteur en sciences, dirige le groupe Dispositifs de diagnostic au Centre technologique LEITAT, o\u00f9 il est chercheur principal depuis 2018. Ses recherches portent sur les diagnostics au point de soins, les tests de flux lat\u00e9ral et les plateformes microfluidiques avanc\u00e9es pour la d\u00e9tection rapide des maladies. Titulaire d'une licence et d'un doctorat en chimie analytique de l'Universit\u00e9 de Barcelone, il a occup\u00e9 des postes de chercheur au Centre d'excellence ARC pour la science des \u00e9lectromat\u00e9riaux (Australie), ainsi que des postes de chercheur \u00e0 l'Universit\u00e9 de Wollongong (Australie) et \u00e0 la DCU (Irlande). Fort de plus de 15 ans d'exp\u00e9rience, il a d\u00e9velopp\u00e9 des solutions de diagnostic innovantes int\u00e9grant des biocapteurs, l'\u00e9lectrofluidique et des syst\u00e8mes d'organes sur puce. <\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Universidad de Oviedo<\/a><\/span>

Maria Teresa Fern\u00e0ndez<\/h3><\/div><\/div>

M. Teresa Fern\u00e1ndez est Professeure des universit\u00e9s en Biochimie et Biologie Mol\u00e9culaire \u00e0 l\u2019Universit\u00e9 d\u2019Oviedo et directrice de l\u2019Institut de Biotechnologie des Asturies (IUBA). Dipl\u00f4m\u00e9e en Chimie, puis en Biochimie, elle a travaill\u00e9 comme chercheuse postdoctorale au National Cancer Institute (NIH, USA). Depuis 1990, elle codirige avec le Dr A. Novelli un groupe en Neurosciences \u00e0 l\u2019Universit\u00e9 d\u2019Oviedo. Son activit\u00e9 de recherche porte sur les m\u00e9canismes de la neurotoxicit\u00e9 et de la neuroprotection, en utilisant des cultures primaires de neurones et de cellules gliales du syst\u00e8me nerveux central, ainsi que l\u2019\u00e9tude de l\u2019activit\u00e9 \u00e9lectrique neuronale \u00e0 l\u2019aide de la m\u00e9thode des r\u00e9seaux de micro\u00e9lectrodes (MEA) pour l\u2019analyse des signaux extracellulaires g\u00e9n\u00e9r\u00e9s par les r\u00e9seaux neuronaux cultiv\u00e9s in vitro sur micro\u00e9lectrodes.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
Sapienza University of Rome<\/a><\/span>

Giovanni Fabbrini<\/h3><\/div><\/div>

Le professeur Giovanni Fabbrini est professeur titulaire de neurologie et directeur du d\u00e9partement de neurosciences humaines de l'universit\u00e9 Sapienza de Rome, o\u00f9 il dirige \u00e9galement la clinique des troubles du mouvement et de la maladie de Parkinson. Il a obtenu son doctorat en m\u00e9decine (1981) et sa sp\u00e9cialisation en neurologie (1985) \u00e0 l'universit\u00e9 de L'Aquila, puis a effectu\u00e9 une formation \u00e0 la recherche en tant que chercheur invit\u00e9 aux NIH (1984-1987) et professeur invit\u00e9 \u00e0 l'universit\u00e9 Washington (1991). Il est pr\u00e9sident de la Soci\u00e9t\u00e9 italienne de la maladie de Parkinson (LIMPE-DISMOV) et auteur de plus de 330 publications index\u00e9es, avec un indice h de 63.<\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n\n\n\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n
\"\"<\/div>
University of Newcastle <\/a><\/span>

Murray Cairns<\/h3><\/div><\/div>

Professor Murray Cairns is head of the Centre for Complex Trait Genetics and Precision Medicine at the University of Newcastle, and the Chair of the Hunter Medical Research Institute Precision Medicine Research Program. Cairns has over 200 career publications, in journals such as Nature, Science, Cell, Nature Biotechnology, Nature Reviews Genetics, Nature Genetics, Nature Communications, Circulation.
Collectively, these have attracted more than 31,000 citations and highlight a significant international reputation in complex trait genetics and functional genomics. Cairns is an editorial board member of Epigenomics, American Journal of Medical Genetics, MicroRNA, Frontiers in Non-Coding RNA, Journal of RNA and Genomics, BioMedInformatics, International Journal of Molecular Science, Open Journal of Genomics.<\/em><\/p><\/div><\/div><\/div>\n\n\n\n

\n
\"\"<\/a><\/figure>\n\n\n\n
\"\"<\/a><\/figure>\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n
\n
<\/div><\/div>\n<\/div><\/div>\n\n\n\n
\n
\n
\n
\"\"<\/figure><\/div>\n<\/div>\n\n\n\n
\n

Ce projet a re\u00e7u un financement dans le cadre du programme HORIZON-HLTH-2024-DISEASE-03 \u00e0 deux \u00e9tapes de l\u2019Union europ\u00e9enne. grant agreement No 101156370<\/a>.
Les points de vue et opinions exprim\u00e9s sont toutefois ceux de l\u2019auteur ou des auteurs uniquement et ne refl\u00e8tent pas n\u00e9cessairement ceux de l\u2019Union europ\u00e9enne ou de HORIZON-RIA. Ni l\u2019Union europ\u00e9enne ni l\u2019autorit\u00e9 de financement ne peuvent \u00eatre tenues responsables.<\/p>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n

<\/p>","protected":false},"excerpt":{"rendered":"

The Team<\/p>","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"enabled","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"class_list":["post-5137","page","type-page","status-publish","hentry"],"yoast_head":"\nTeam - V\u03b1MPiRE<\/title>\n<meta name=\"description\" content=\"Parkinson's disease early detection\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.vampire-eu.com\/fr\/team\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Team - V\u03b1MPiRE\" \/>\n<meta name=\"twitter:description\" content=\"Parkinson's disease early detection\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/vampire-opengraph-1200x630-1.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"19 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.vampire-eu.com\/team\/\",\"url\":\"https:\/\/www.vampire-eu.com\/team\/\",\"name\":\"Team - V\u03b1MPiRE\",\"isPartOf\":{\"@id\":\"https:\/\/www.vampire-eu.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg\",\"datePublished\":\"2025-05-15T07:59:48+00:00\",\"dateModified\":\"2026-01-20T15:52:48+00:00\",\"description\":\"Parkinson's disease early detection\",\"breadcrumb\":{\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.vampire-eu.com\/team\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#primaryimage\",\"url\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg\",\"contentUrl\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.vampire-eu.com\/team\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.vampire-eu.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Team\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.vampire-eu.com\/#website\",\"url\":\"https:\/\/www.vampire-eu.com\/\",\"name\":\"V\u03b1MPiRE\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.vampire-eu.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.vampire-eu.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.vampire-eu.com\/#organization\",\"name\":\"V\u03b1MPiRE\",\"url\":\"https:\/\/www.vampire-eu.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png\",\"contentUrl\":\"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png\",\"width\":512,\"height\":512,\"caption\":\"V\u03b1MPiRE\"},\"image\":{\"@id\":\"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/showcase\/biosomics\/about\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Team - V\u03b1MPiRE","description":"Parkinson's disease early detection","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.vampire-eu.com\/fr\/team\/","twitter_card":"summary_large_image","twitter_title":"Team - V\u03b1MPiRE","twitter_description":"Parkinson's disease early detection","twitter_image":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/vampire-opengraph-1200x630-1.jpg","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"19 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.vampire-eu.com\/team\/","url":"https:\/\/www.vampire-eu.com\/team\/","name":"Team - V\u03b1MPiRE","isPartOf":{"@id":"https:\/\/www.vampire-eu.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.vampire-eu.com\/team\/#primaryimage"},"image":{"@id":"https:\/\/www.vampire-eu.com\/team\/#primaryimage"},"thumbnailUrl":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg","datePublished":"2025-05-15T07:59:48+00:00","dateModified":"2026-01-20T15:52:48+00:00","description":"Parkinson's disease early detection","breadcrumb":{"@id":"https:\/\/www.vampire-eu.com\/team\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.vampire-eu.com\/team\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.vampire-eu.com\/team\/#primaryimage","url":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg","contentUrl":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/05\/BobJenkinsHamley-512.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.vampire-eu.com\/team\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.vampire-eu.com\/"},{"@type":"ListItem","position":2,"name":"Team"}]},{"@type":"WebSite","@id":"https:\/\/www.vampire-eu.com\/#website","url":"https:\/\/www.vampire-eu.com\/","name":"V\u03b1MPiRE","description":"","publisher":{"@id":"https:\/\/www.vampire-eu.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.vampire-eu.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.vampire-eu.com\/#organization","name":"V\u03b1MPiRE","url":"https:\/\/www.vampire-eu.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png","contentUrl":"https:\/\/www.vampire-eu.com\/wp-content\/uploads\/2025\/02\/cropped-cropped-V\u03b1MPiRE.png","width":512,"height":512,"caption":"V\u03b1MPiRE"},"image":{"@id":"https:\/\/www.vampire-eu.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/showcase\/biosomics\/about"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"trp-custom-language-flag":false},"uagb_author_info":{"display_name":"Pedro Sanchez","author_link":"https:\/\/www.vampire-eu.com\/fr\/author\/slpedro\/"},"uagb_comment_info":0,"uagb_excerpt":"The Team","_links":{"self":[{"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/pages\/5137","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/comments?post=5137"}],"version-history":[{"count":59,"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/pages\/5137\/revisions"}],"predecessor-version":[{"id":5583,"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/pages\/5137\/revisions\/5583"}],"wp:attachment":[{"href":"https:\/\/www.vampire-eu.com\/fr\/wp-json\/wp\/v2\/media?parent=5137"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}